Target unmet needs ZyVersa focuses on renal and inflammatory diseases with two licensed product platforms, presenting a clear path to address gaps in treatment for kidney disease and chronic inflammation.

Lead program clarity VAR 200 aims to remove excess intracellular lipids in the kidney filtration system, offering a potential differentiated renal therapy that could complement or replace existing standards for patients at risk of end-stage kidney disease.

Inflammation platform IC 100 inflammasome inhibitor targets initiation and perpetuation of damaging inflammation across multiple diseases, signaling cross‑segment upsell opportunities into broader inflammatory and metabolic conditions.

Funding runway With ongoing funding of its clinical programs and prior flexible financing, there is a message of financial momentum that can be leveraged to de-risk partnerships and co‑development deals with larger biotech or specialty pharma.

Strategic partnerships Recent investor activity and a focused development plan create openings for collaboration around VAR 200 and IC 100, including joint development, supply agreements, or milestone‑driven partnerships to accelerate clinical progress and commercialization readiness.